US 12,433,952 B2
Antibody-drug conjugates targeting folate receptor alpha and methods of use
James R. Rich, Vancouver (CA); Stuart Daniel Barnscher, Vancouver (CA); Mark Edmund Petersen, Vancouver (CA); Raffaele Colombo, Vancouver (CA); Michael G. Brant, Vancouver (CA); Manuel Michel Auguste Lasalle, Vancouver (CA); Rupert H. Davies, Seattle, WA (US); Dunja Urosev, Vancouver (CA); Sukhbir Singh Kang, Vancouver (CA); Peter Wing Yiu Chan, Vancouver (CA); Samir Das, Vancouver (CA); Andrea Hernandez Rojas, Vancouver (CA); Robert William Gene, Vancouver (CA); Ada G. H. Young, Vancouver (CA); Samuel Oliver Lawn, Vancouver (CA); Danny Chui, Vancouver (CA); Duncan Browman, Vancouver (CA); and Brandon Clavette, Vancouver (CA)
Assigned to Zymeworks BC Inc., Vancouver (CA)
Filed by ZYMEWORKS BC INC., Vancouver (CA)
Filed on May 29, 2024, as Appl. No. 18/677,564.
Application 18/677,564 is a continuation of application No. PCT/CA2023/050406, filed on Mar. 24, 2023.
Claims priority of provisional application 63/450,607, filed on Mar. 7, 2023.
Claims priority of provisional application 63/417,250, filed on Oct. 18, 2022.
Claims priority of provisional application 63/324,003, filed on Mar. 25, 2022.
Prior Publication US 2024/0424125 A1, Dec. 26, 2024
Int. Cl. A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 47/68037 (2023.08) [A61K 47/6849 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07K 16/28 (2013.01)] 30 Claims
 
1. An antibody-drug conjugate having a structure:

OG Complex Work Unit Chemistry
wherein:
T is an anti-folate receptor alpha (anti-FRα) antibody construct comprising an antigen-binding domain operably linked to an IgG Fc region, the antigen-binding domain comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) and three light chain CDRs (LCDR1, LCDR2, and LCDR3), wherein:
(i) the HCDR1 amino acid sequence comprises a sequence as set forth in any one of SEQ ID NOs: 20, 23, 26, 28 or 31; the HCDR2 amino acid sequence comprises a sequence as set forth in any one of SEQ ID NOs: 21, 24, 29, 32 or 51, and the HCDR3 amino acid sequence comprises a sequence as set forth in any one of SEQ ID NOs: 22, 25 or 30, and
(ii) the LCDR1 amino acid sequence comprises a sequence as set forth in any one of SEQ ID NOs: 40, 45 or 65; the LCDR2 amino acid sequence comprises a sequence as set forth in any one of SEQ ID NOs: 41, 44 or 46, and the LCDR3 amino acid sequence comprises a sequence as set forth in any one of SEQ ID NOs: 42 or 47,
and wherein n is between about 4 and about 8.